Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 83,256 | 67,465 | 63,716 | 97,679 | 44,189 |
| Receivables | 2,328 | 4,244 | 7,264 | 780 | 364 |
| Inventories | 193 | 1,160 | 441 | 704 | 443 |
| TOTAL | $89,498 | $74,442 | $74,013 | $101,177 | $45,594 |
| Non-Current Assets | |||||
| PPE Net | 1,847 | 2,708 | 2,550 | 2,283 | 498 |
| TOTAL | $1,847 | $2,708 | $2,550 | $2,283 | $498 |
| Total Assets | $91,345 | $77,150 | $76,563 | $103,460 | $46,091 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,820 | 2,821 | 6,669 | 3,056 | 2,017 |
| Accrued Expenses | 8,606 | 6,084 | 3,996 | 2,502 | 1,011 |
| TOTAL | $15,343 | $14,397 | $14,218 | $8,864 | $4,251 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 2,917 | 5,493 | 3,554 | 3,306 | 1,222 |
| TOTAL | $55,651 | $55,849 | $46,964 | $36,828 | $18,760 |
| Total Liabilities | $70,994 | $70,246 | $61,183 | $45,693 | $23,010 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 101,390 | 91,712 | 82,946 | 78,433 | 71,042 |
| Common Shares | 101 | 92 | 82 | 78 | 69 |
| Retained earnings | -225,252 | -172,010 | -113,650 | -64,995 | -41,099 |
| TOTAL | $20,352 | $6,903 | $15,380 | $57,768 | $23,081 |
| Total Liabilities And Equity | $91,345 | $77,149 | $76,563 | $103,460 | $46,091 |